Catheter-directed microsphere embolization of the prostatic arteries — a minimally invasive, sexual-function-sparing alternative to TURP
Before any catheter is introduced, CT angiography (or MR angiography) of the pelvis is used to build a personalized road map of the internal iliac arterial tree. Because the prostatic artery is small (0.5–2.5 mm), highly variable in origin, and frequently shares a common trunk with the vesical, rectal, or internal pudendal arteries, pre-procedural mapping is what separates a 3-hour procedure from a 1-hour one.
Benign prostatic hyperplasia (BPH) causes lower urinary tract symptoms (LUTS) in most men over 60. TURP has been the surgical gold standard for 80+ years, but it requires anesthesia, carries meaningful rates of retrograde ejaculation, bleeding, and a hospital stay. Medical therapy (alpha-blockers, 5-ARIs) helps symptoms modestly but does not shrink very large glands and requires lifelong daily dosing.
PAE, developed from uterine fibroid embolization technique and first reported for BPH by João Martins Pisco (Portugal, 2008–2011), offers a third pathway: an interventional radiology procedure performed under local anesthesia and conscious sedation that starves the hyperplastic adenoma of its arterial blood supply, letting it shrink on its own — without cutting any tissue and without traversing the urethral sphincter or neurovascular bundles that control sexual function.
PAE is uniquely suited to men with very large prostates (>80–100 mL) who are poor surgical candidates, on anticoagulation, or who prioritize preserving ejaculatory and erectile function above maximal symptom relief.
A dedicated pelvic CTA (or increasingly, cone-beam CT during the procedure) is obtained to trace the prostatic artery from its origin off the internal iliac artery anterior division down to the prostate capsule. The Carnevale classification describes 5 common origin patterns:
• Type I: PA arises from a common trunk with the superior vesical artery • Type II: PA arises from the internal pudendal artery • Type III: PA arises from the obturator artery • Type IV: PA arises from the inferior vesical/middle rectal artery • Type V (rare): PA arises directly from the external iliac artery or an accessory pathway
Recognizing the variant before the case dramatically shortens catheterization time and reduces contrast/radiation dose, because the operator already knows roughly where to look instead of probing the pelvis vessel-by-vessel under live fluoroscopy.
Good PAE candidates typically have:
• Moderate-to-severe LUTS (IPSS ≥13) refractory to or intolerant of medical therapy • Prostate volume generally >40 mL, with PAE's comparative advantage growing for very large glands (80–200+ mL) where TURP/HoLEP operative time and morbidity rise steeply • High surgical or anesthesia risk, anticoagulation that cannot be safely stopped, or a strong personal priority on preserving antegrade ejaculation • Patent, catheterizable iliac and prostatic arteries — severe bilateral iliac occlusive disease or a heavily calcified, corkscrew prostatic artery predicts technical failure
Patients with active urinary tract infection, bladder stones, large bladder diverticula, or suspected prostate cancer are generally poor candidates and need TURP/HoLEP or oncologic workup instead.
PAE is performed entirely from inside the vascular tree. A single needle puncture — most often the common femoral artery, increasingly the radial artery for patient comfort and fewer access-site complications — gives the interventional radiologist a continuous, unbroken path all the way to arterioles less than a millimeter wide inside the prostate.
Under ultrasound guidance, a micropuncture needle accesses the common femoral (transfemoral) or radial (transradial) artery and a vascular sheath is placed. A 4–5F guiding catheter is advanced over a hydrophilic guidewire through the external iliac artery, around the pelvic brim, and selectively into the internal iliac artery — the vessel that ultimately supplies the bladder, rectum, prostate and pelvic floor.
From there, a microcatheter (as small as 1.9–2.4 Fr, roughly 0.6–0.8 mm outer diameter) is coaxially advanced through the guiding catheter and threaded, often over a steerable microwire, into the anterior division of the internal iliac artery and then superselectively into the prostatic artery itself — a vessel frequently thinner than a strand of spaghetti and running alongside atherosclerotic plaque in older men.
Radial access has grown rapidly because it lets patients sit up, eat, and walk almost immediately after the sheath is removed, with a near-zero rate of the major bleeding/pseudoaneurysm complications seen at the femoral site — the same shift interventional cardiology made a decade earlier.
Once the microcatheter tip is thought to be in the prostatic artery, many centers perform an intraprocedural cone-beam CT (CBCT) — a 3D rotational X-ray acquisition with contrast injected through the catheter. Dedicated vessel-tracking software overlays the reconstructed 3D prostatic vasculature onto the live 2D fluoroscopy image, confirming catheter position and revealing any dangerous anastomoses to the bladder, rectum, or penis before a single microsphere is injected.
This roadmap step is one of the biggest contributors to PAE's improving safety profile over the last decade: non-target embolization causing bladder or rectal ischemia dropped from case-report-level rarity to near-zero at high-volume centers once routine CBCT confirmation became standard.
Unlike a surgical field the operator can see and feel, the entire PAE procedure is navigated blind, guided only by 2D X-ray projections. The internal iliac anterior division and prostatic artery are notoriously tortuous, and in elderly men — the exact population that needs BPH treatment — this tortuosity is compounded by atherosclerotic narrowing, calcification, and occasional complete occlusion.
In roughly 5–20% of attempted cases (higher in some series for bilateral success), one or both prostatic arteries cannot be safely and selectively catheterized, and the case is converted to unilateral embolization or aborted. This anatomic failure rate — not the embolization step itself — is the single largest limitation of PAE relative to surgery, which bypasses the vascular tree entirely.
With the microcatheter locked superselectively inside the prostatic artery and confirmed free of dangerous collateral pathways, the operator slowly hand-injects a suspension of calibrated embolic microspheres under continuous fluoroscopic observation — the step that actually delivers PAE's therapeutic effect.
The modern standard is the PErFecTED technique (Proximal Embolization First, Then Embolize Distal), described by Carnevale in 2014. Rather than embolizing from wherever the catheter first sits, the microcatheter (or microwire) is pushed as distally as possible into the intraprostatic arterial branches before injection begins — allowing microspheres to penetrate deep into the peripheral, capillary-level bed of the adenoma rather than clogging only the proximal trunk.
Deeper, more distal penetration produces significantly greater and more durable prostate volume reduction and symptom improvement than proximal-only embolization, because it starves the maximum volume of hyperplastic tissue rather than leaving collateral flow from adjacent branches to partially rescue the gland.
The visual endpoint operators watch for is near-stasis flow — contrast that used to wash out in 1–2 heartbeats now lingers for 5+ heartbeats, and the fine arterial network takes on a stark, pruned "tree-in-winter" appearance on the final angiogram, confirming the peripheral bed has been sufficiently occluded.
Two calibrated, spherical embolic particle types dominate PAE practice:
• Tris-acryl gelatin microspheres (Embosphere) — the first agent FDA-cleared specifically referencing PAE (2017); compressible, uniform, resist clumping, most widely used size range 100–300 μm • Non-spherical or spherical PVA (polyvinyl alcohol) particles — cheaper, historically used, slightly less predictable calibration and higher clumping tendency than tris-acryl spheres
Smaller particles (100–200 μm) penetrate further into the peripheral, capillary-adjacent bed and are associated with greater volume reduction, but carry a theoretically higher (still low, <2%) risk of non-target ischemia through collateral vessels; larger particles (300–500 μm) are more forgiving but achieve less distal penetration. Most contemporary protocols use 100–300 μm as the working range balancing efficacy against safety.
Maximal, durable symptom improvement requires bilateral embolization — both the left and right prostatic arteries must be catheterized and embolized, since each supplies roughly one lateral lobe. Unilateral embolization (performed when the contralateral artery cannot be safely catheterized) still produces meaningful improvement in many patients but with a smaller average effect size and higher retreatment rate.
Before injecting in either artery, the operator scrutinizes the CBCT roadmap and test angiogram for anastomoses toward the internal pudendal (penile), vesical (bladder), or rectal arterial territories. When present, these are protectively coil-occluded or the catheter is repositioned distal to them before embolic spheres are released, preventing the rare but serious complications of penile, bladder, or rectal ischemia.
Unlike TURP, whose debulking effect is immediate and visible on the operating table, PAE's benefit unfolds slowly. The embolized adenoma undergoes a biological process of coagulative ischemic necrosis, inflammatory resorption, and fibrous involution that plays out over weeks to months — patients are counseled that early symptom relief may lag behind the imaging changes.
Within hours of embolization, the microsphere-occluded arterioles cut off oxygen and nutrient delivery to large volumes of hyperplastic glandular and stromal tissue. Over the following days, ischemic cells undergo coagulative necrosis; macrophages infiltrate and gradually resorb the necrotic tissue over weeks; and the region is progressively replaced by contracted fibrous scar rather than viable hyperplastic epithelium and stroma.
This is fundamentally different from surgical debulking (TURP/HoLEP), where tissue is mechanically removed in the operating room and the anatomical effect is complete before the patient leaves the table. With PAE, the prostate imaged one week after the procedure often still looks nearly unchanged in volume, or even transiently swollen from edema — the real shrinkage becomes measurable on MRI or ultrasound at 1, 3, and 6 months.
Most patients experience a self-limited constellation of symptoms in the first several days after PAE — pelvic/perineal pain, dysuria, urinary frequency or urgency, mild hematuria, hematospermia, low-grade fever, and fatigue — collectively called post-embolization syndrome. It reflects the acute inflammatory response to the induced ischemia and typically resolves within 3–7 days with NSAIDs, alpha-blockers, and reassurance.
This is one of PAE's clear practical advantages: post-embolization syndrome, while common, is rarely severe enough to require hospital readmission, and most patients return to normal daily activity within 2–3 days — compared to the multi-week catheter and activity-restriction recovery typical after TURP or open/laparoscopic simple prostatectomy.
Response is tracked with a combination of:
• Prostate volume (MRI or transrectal ultrasound) — mean reduction of roughly 20–30% by 3–6 months in most published series, with some large-gland cohorts reporting up to ~35–40% • International Prostate Symptom Score (IPSS) — typically falls progressively over the first 3 months and then plateaus • Peak urinary flow rate (Qmax) — improves more modestly and more slowly than after TURP • Post-void residual (PVR) volume — decreases as bladder outlet resistance falls
Because the mechanism is a slow biological involution rather than a mechanical resection, roughly 10–20% of patients are "non-responders" or partial responders whose adenoma does not shrink enough to relieve obstruction, most often correlating with unilateral-only embolization or a large fibromuscular (rather than adenomatous) component of their hyperplasia.
Randomized trials and large registries (including the UK ROPE registry and several PAE-vs-TURP RCTs) now give a consistent picture: PAE reliably improves symptoms and quality of life with a markedly gentler recovery and near-complete preservation of sexual function, but on average achieves a smaller improvement in symptom score and urinary flow than TURP, with a meaningfully higher retreatment rate.
Across RCTs (e.g., Gao et al. 2014; the UK-ROPE registry; Abt et al. 2018 BJU/BMJ trial; Ray et al. 2018), PAE consistently produces clinically meaningful reductions in IPSS (commonly 10–15 points, roughly 40–50% relative improvement) and modest gains in peak flow rate (Qmax typically +3–5 mL/s). TURP, by mechanically removing obstructing tissue, produces larger average gains — IPSS improvements often exceeding 65–70% and Qmax gains of +10–15 mL/s or more.
Patient-reported quality-of-life scores after PAE are often comparable to TURP even when objective IPSS/Qmax numbers are lower, reflecting how much patients value the avoided anesthesia, avoided catheter, faster return to work, and preserved sexual function.
Because PAE never instruments the urethra, bladder neck, or verumontanum, and does not disturb the periprostatic neurovascular bundles that TURP/HoLEP/prostatectomy can injure, rates of retrograde ejaculation after PAE are consistently below 10% (many series report 0–5%), compared with roughly 65–75% after TURP and effectively near-universal after simple prostatectomy. Erectile function is essentially unaffected by PAE in the large majority of published cohorts, and some studies even report modest improvement, likely from better overall pelvic blood flow and symptom relief.
For sexually active men — particularly younger BPH patients — this single difference is often the deciding factor in choosing PAE over a more symptom-effective surgical option.
In head-to-head trials, roughly 65–75% of men undergoing TURP report new retrograde ("dry") ejaculation, versus well under 10% after PAE — making preserved ejaculatory function PAE's clearest and most reproducible advantage over every surgical alternative.
PAE's Achilles' heel is anatomic: unfavorable, tortuous, or atherosclerotic prostatic arterial anatomy causes technical failure of superselective bilateral catheterization in roughly 5–20% of attempted cases, and this rate rises further in patients with severe peripheral vascular disease or prior pelvic surgery/radiation. When only unilateral embolization is achieved, both symptom improvement and durability are reduced.
For extremely large glands (some centers cite thresholds above ~150–200 mL), or where an operator with high PAE volume/expertise is unavailable, enucleation techniques such as HoLEP remain preferred, since they can debulk essentially unlimited gland volume in a single session with more predictable, immediate, and durable relief of obstruction — at the cost of anesthesia, catheterization, and a much higher rate of retrograde ejaculation. PAE is best understood not as a universal TURP replacement, but as a complementary option for a specific patient profile: large or very large glands, high surgical risk, anticoagulation, or a strong preference to preserve ejaculatory function.
| Product | Indication | Trial Design | Key Result |
|---|---|---|---|
| Prostate Artery Embolization | Local anesthesia, outpatient/overnight; back to normal activity in 2–3 days | Catheter-directed ischemic involution over weeks–months; ~20–30% volume reduction | Sexual function preserved (<10% retrograde ejac.); low major complication rate |
| TURP (Transurethral Resection) | Spinal/general anesthesia, 1–3 day stay, catheter 1–3 days, ~2–4 wk recovery | Immediate mechanical tissue resection; largest, most durable flow/symptom gain | Largest IPSS/Qmax improvement (~65–70%+); lowest retreatment rate (~3–5%) |
| Medical Therapy (α-blocker + 5-ARI) | No procedure; daily oral dosing, indefinite; no recovery time | Smooth-muscle relaxation (α-blocker) + slow glandular shrinkage (5-ARI, months) | Non-invasive, reversible; modest symptom relief (~30–40% IPSS) but no volume debulking |